List of Boniva drug patents
Boniva is owned by Hoffmann La Roche.
Boniva contains Ibandronate Sodium.
Boniva has a total of 3 drug patents out of which 0 drug patents have expired.
Boniva was authorised for market use on 16 May, 2003.
Boniva is available in tablet;oral dosage forms.
Boniva can be used as treatment and prevention of osteoporosis, treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid.
The generics of Boniva are possible to be released after 06 May, 2023.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7192938 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 months from now) | |
| US7718634 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 months from now) | |
| US7410957 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(2 months from now) | |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 16 May, 2003
Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention of osteoporosis
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic